ANI Pharma Q1 rev $237.5M (+20.5%); raises FY 2026 guidance, authorizes $100M buyback

ANI PHARMACEUTICALS INC

2026-Q1 EPS reported $1.28 vs consensus $1.33 ▼ miss (-3.8%)

Q1 net revenue $237.5M (+20.5% YoY); GAAP diluted EPS $1.28; adj non-GAAP diluted EPS $2.05.
Cortrophin Gel rev $75.1M (+42.1%); ILUVIEN rev $19.3M (+19.5%); Generics rev $105.4M (+6.8%).
Raised FY 2026 guidance: rev $1,080M-$1,140M; adj EBITDA $285M-$300M; adj diluted EPS $9.19-$9.69.
Board authorized $100M share repurchase program through May 2029; cash from operations $58.4M in Q1.
Harmony Agreement contributed $15M upfront + $6.5M royalties; $10M milestone expected in Q2/Q3 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

ANI PHARMACEUTICALS INC reported first quarter ended March 31, 2026 results: revenue $237.5 million, net income $29.5 million, EPS $1.28. Guidance raised.

Period: first quarter ended March 31, 2026
Revenue: $237.5 million
Net income: $29.5 million
EPS: $1.28
Guidance: raised
Result: reported results

Exact text from the filing

ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance • Quarterly net revenues of $237.5 million, an increase of 20.5% year-over-year • Purified Cortrophin ® Gel net revenues of $75.1 million, an increase of 42.1% year-over-year • Quarterly GAAP net income available to common shareholders of $29.5 million; Quarterly adjusted non-GAAP EBITDA of $63.0 million, an increase of 24.1% year-over-year • Diluted GAAP income per share of $1.28 and adjusted non-GAAP diluted earnings per share of $2.05

View on SEC.gov

Browse all earnings releases →

ANI PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001023024-26-000049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.